The latest price target for Organon (NYSE:OGN) was reported by Barclays on February 14, 2025. The analyst firm set a price target for $24.00 expecting OGN to rise to within 12 months (a possible 54.44% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Organon (NYSE:OGN) was provided by Barclays, and Organon maintained their overweight rating.

The last upgrade for Organon & Co happened on September 6, 2022 when Piper Sandler raised their price target to $34. Piper Sandler previously had a neutral for Organon & Co.

The last downgrade for Organon & Co happened on September 6, 2024 when JP Morgan changed their price target from $18 to $20 for Organon & Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Organon, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Organon was filed on February 14, 2025 so you should expect the next rating to be made available sometime around February 14, 2026.

While ratings are subjective and will change, the latest Organon (OGN) rating was a maintained with a price target of $26.00 to $24.00. The current price Organon (OGN) is trading at is $15.54, which is out of the analyst’s predicted range.